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By the appropriate selection of functional peptides and proper accommodation sites, we 
have generated a set of multifunctional proteins that combine selectivity for CXCR4+ cell 
binding and relevant endosomal escape capabilities linked to the viral peptide HA2. In 
particular, the construct T22-GFP-HA2-H6 forms nanoparticles that upon administration in 
mouse models of human, CXCR4+ colorectal cancer, accumulates in primary tumor at levels 
significantly higher than the parental T22-GFP-H6 HA2-lacking version. The in vivo 
application of a CXCR4 antagonist has confirmed the prevalence of the CXCR4+ tumor tissue 
selectivity over unspecific cell penetration, upon systemic administration of the material. 
Such specificity is combined with improved endosomal escape, what overall results in a 
precise and highly efficient tumor biodistribution. These data strongly support the functional 
recruitment as a convenient approach to generate protein materials for clinical applications. 
More precisely, they also support the unexpected concept that enhancing the unspecific 
membrane activity of a protein material does not necessarily compromise, but it can even 
improve, the selective cell targeting offered by an accompanying functional module. 
  





The plasticity of proteins as highly versatile macromolecules allows functional recruitment 
by simple genetic fusion, upon selection of appropriate protein domains [1]. This approach 
permits the combination, in modular polypeptides constructed de novo, of diverse 
functionalities such as self-assembling and specific interaction with cells or cell components, 
what results in functional materials usable in different biomedical applications [2-10]. 
Among other uses, regular nanoscale oligomers are promising carriers for cell-targeted drug 
delivery [11-13], a popular aim when administering cytotoxic drugs in cancer therapies [14-
18]. Protein nanoparticles, because of the above mentioned versatility, can be easily 
functionalized with peptidic ligands of cell surface markers for active targeting and 
subsequent endosome-mediated cell internalization. On the other hand, endosomal escape, 
required for drug delivery, is a major bottleneck when using protein-based drug vehicles [19, 
20], that are sensitive to proteolysis in endocytic compartments. Therefore, under the 
functional recruitment concept, it would be extremely useful to combine precise cell 
targeting (through specific ligands of cell surface markers) and endosomal escape (through 
membrane-active peptides, that unfortunately, lack cell specificity) in single nanoparticles. 
However, how receptor-specific and receptor-unspecific cell contacts, empowered by a 
ligand and a fusogenic peptide respectively, would combine in drug vehicles, is a neglected 
issue. In this context, we have previously functionalized self-assembling protein 
nanoparticles (mostly based on GFP) [21] with the peptide T22, targeted to the highly 
relevant, cancer stem cell marker of CXCR4 [22, 23]. These nanoparticles are formed by ten 
individual T22-GFP-H6 building blocks [21] that keep their native GFP conformation [24], and 
that are stably connected by divalent cations coordinated with the carboxy-terminal 
histidine tails [25].  When conjugated with conventional antitumoral drugs, T22-GFP-H6 
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nanoparticles promote successful unusually high tumor tissue drug accumulation and highly 
selective destruction of metastatic foci in animal models of colorectal cancer [26]. To 
improve drug and vehicle stability during intracellular delivery, we have favoured the 
endosomal escape of the construct by the incorporation of either the fusogenic HA2 peptide 
from the influenza virus hemagglutinin [27-29] or the synthetic pore-forming peptide GW-H1 
[30, 31], into T22-GFP-H6 building blocks, to effectively trigger an early escape from 
endosomes [32]. The resulting modular nanoparticles dramatically gained cell penetrability 
and endosomal escape in cell culture but at expenses of CXCR4 selectivity, that was 
importantly reduced [33, 34]. Despite this preliminary result, how such simultaneous gain of 
penetrability and loss of cell specificity promoted by endosomolytic peptides would affect in 
vivo biodistribution and tumor accumulation of the nanoparticle remained to be assessed.  
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2. Materials and methods 
2.1. Protein production and purification 
Modular proteins T22-HA2-GFP-H6 and T22-GFP-HA2-H6 (Figure 1A) were produced in 
Escherichia coli Origami B strain (BL21, OmpT-, Lon-, TrxB-, Gor-; Novagen). Protein 
production was induced at an OD550 of ~ 0.5 - 0.7 by the addition of 0.1 mM and 0.01 mM 
of isopropyl-β-thiogalactopyronaside (IPTG), respectively. After overnight production at 
16 °C (T22-HA2-GFP-H6) and 20 °C (T22-GFP-HA2-H6) cells were harvested by centrifugation 
(5,000 g, 15 min, 4 ºC) and stored at -80 ºC until use. Bacterial pellets were resuspended in 
Wash buffer (20 mM Tris pH 8.0, 500 mM NaCl and 10 mM imidazole) in presence of a 
protease inhibitor cocktail (Complete EDTA-Free, Roche) for purification purposes. Then, 
bacterial cells were disrupted by French Press at 1,200 psi for 3 rounds (Thermo FA-078A) 
and centrifuged (15,000 g, 45 min, 4 ºC) to separate the soluble from the insoluble fraction. 
After 0.22 µm filtration, proteins were purified by Immobilized Metal Affinity 
Chromatography (IMAC) using a HiTrap Chelating HP column (GE Healthcare) in an ÄKTA 
pure system (GE Healthcare). Proteins were eluted by a one-step of Elution buffer (20 mM 
Tris pH 8.0, 500 mM NaCl and 500 mM imidazole) and further dialyzed against 166 mM 
NaCO3H (T22-HA2-GFP-H6) and 166 mM NaCO3H 333 mM NaCl buffers (T22-GFP-HA2-H6).  
 
2.2 Physicochemical characterization  
Protein integrity and purity was assessed by Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and Western blotting using an anti-His monoclonal antibody 
(Santa Cruz Biotechnology). The molecular mass of T22-HA2-GFP-H6 and T22-GFP-HA2-H6 
proteins was determined by Matrix-Assisted Laser Desorption Ionization Time-of-Flight 
(MALDI-TOF) mass spectrometry, while the volume size distribution was determined by 
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Dynamic Light Scattering (DLS) at 633 nm in a Zetasizer Nano ZS (Malvern Instruments 
Limited). Additionally, fluorescence of the GFP-based nanoparticles was determined by a 
Varian Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies), through an 
excitation wavelength at 450 nm and detection at 510 nm. Protein stability, was assessed in 
human sera (Sigma-Aldrich) at 37 ºC for 0, 2, 5 and 24 h. Then, protein integrity was 
evaluated by Western blot using an anti-His monoclonal antibody (Santa Cruz Biotechnology) 
for the specific immunodetection of the His-tag. Additionally, Precision Plus Protein All Blue 
Standards (BioRad) was used to confirm the expected molecular weight of the samples. 
 
2.3 Cell culture and flow cytometry 
CXCR4+ HeLa cells were maintained in MEM Alpha (Minimum Essential Medium α, Gibco) 
supplemented with 10 % foetal bovine serum (Gibco) at 37 °C and 5 % CO2 in a humidified 
atmosphere. In order to assess in vitro the CXCR4 specificity of HA2-bearing proteins, HeLa 
cells were scattered (30,000 cells/well) in 24-well plates and incubated during 24 h at 37 ºC 
until reaching 70 % confluence. Then, the antagonist AMD3100, which is expected to inhibit 
the interaction between T22 and CXCR4 receptor, was added at 1:10 ratio 1 h prior to 
protein incubation. Finally, T22-HA2-GFP-H6 and T22-GFP-HA2-H6 were incubated for 1 h at 
a final concentration of 0.1 µM. The obtained samples (performed in duplicate) were 
analysed by a FACS-Canto system (Becton Dickinson) using a 15 mW air-cooled argon ion 
laser at 488 nm excitation. 
 
2.4 Confocal laser scanning microscopy 
For confocal studies of nanoparticle uptake by cells, HeLa cell line was cultured on Mat-Teck 
culture dishes (Mat Tek Corp.). Protein nanoparticles were added at 0.5 μM, and after 24 h 
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of exposure, nuclei were labelled with 5 µg/ml Hoechst 33342 (Molecular Probes) and 
plasma membranes with 2.5 µg/ml CellMaskTM Deep Red (Molecular Probes), for 5 min in 
absence of light. Live cells were washed in PBS (Sigma-Aldrich) and recorded with a TCS-SP5 
confocal laser scanning microscope (Leica Microsystems) using a Plan Apo 63x / 1.4 (oil HC x 
PL APO lambda blue) objective. Hoechst 33342 was excited with a blue diode (405 nm) and 
detected within a 415-460 nm range. Proteins were excited by the 488 nm argon laser line 
and detected within a 525-545 nm range. CellMask was excited with a HeNe laser (633 nm) 
and within a 650-775 nm range. To determine precise intracellular localization, stacks of 20 
to 30 sections were collected every 0.5 µm along the cell thickness. The obtained projections 
of the series were generated with Leica LAS X software, and three-dimensional models were 
produced using Imaris v. 7.2.1 software (Bitplane).    
 
2.5 Ultrastructural characterization 
The ultrastructure of the nanoparticles was evaluated with a high resolution electron 
microscope at a nearly native state. Drops of 3 µl of each nanoparticle samples (T22-GFP-H6, 
T22-HA2-GFP-H6 and T22-GFP-HA2-H6) at a concentration of 0.25 µg/µl were directly 
deposited on conductive silicon wafers (Ted Pella Inc.) for 1 min, cleared few seconds in 
deionized water, air dried, and immediately observed without coating in a FESEM Merlin 
(Zeiss) operating at 1 kV and equipped with a high resolution in-lens secondary electron 
detector. 
 
2.6 In vivo biodistribution studies 
All in vivo experiments were approved by the institutional animal Ethics Committee of 
Hospital Sant Pau. Five-week-old female Swiss nu/nu mice weighing between 18 and 20 g 
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(Charles River) and maintained in specific-pathogen-free (SPF) conditions, were used for the 
in vivo biodistribution studies. We used a subcutaneous colorectal cancer mouse model 
derived from the patient sample M5. To generate this model, 10 mg of M5 tumor tissue 
obtained from a donor animal were implanted in the subcutis of Swiss nu/nu. When tumors 
reached a volume of approximately 500 mm3 we performed biodistribution assays of both 
T22-HA2-GFP-H6 and T22-GFP-HA2-H6 nanoparticles at three different times, namely 2, 5 
and 24 h. We used as a control of biodistribution the T22-GFP-H6 nanoparticle. Each group 
of mice (n=2) received 200 µg single i.v. bolus of one of these three nanoparticles. Control 
animals (n=2) were i.v. administered with 150 µl of buffer. At 2, 5 and 24 hours after the i.v. 
injection, mice were euthanized and subcutaneous tumors and normal organs, including 
brain, lung and heart, kidney, liver, and bone marrow were collected. Biodistribution of 
fluorescent nanoparticles was determined measuring ex vivo the fluorescence emitted by 
tumors and normal organs using the IVIS Spectrum equipment (PerkinElmer Inc). The 
fluorescent signal (FLI) was first digitalized, displayed as a pseudocolor overlay, and 
expressed as radiant efficiency. FLI values were calculated subtracting the FLI signal from the 
protein-treated mice by the FLI auto-fluorescent signal of control mice. 
 
2.7 In vivo competition assays 
The selectivity of the T22-GFP-HA2-H6 nanoparticle for CXCR4+ tissues was analyzed in the 
same M5 subcutaneous CRC mouse model. For competition studies we used the CXCR4 
antagonist AMD3100 (Sigma-Aldrich) and T22-GFP-H6 as a control of selectivity. Mice were 
randomized in 5 groups (n=2). The T22-GFP-H6 and T22-GFP-HA2-H6 groups received a 200 
µg i.v. bolus of the corresponding protein. The AMD3100 competition groups were 
subcutaneously administered with three doses of 10 mg/kg of AMD3100 (1 h before, and 1 
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and 2 h after the nanoparticles injection). The control group received a i.v. bolus of buffer. 
Mice were euthanized 5 h after nanoparticles injection and the GFP fluorescence emitted by 
tumors and non-target organs was determined. 
 
2.8 Histopathology and toxicity in normal organs 
Sections of paraffin-embedded samples of non-target organs (brain, lung and heart, kidney, 
liver, and bone marrow) were hematoxylin and eosin (H&E) stained and the presence of 
toxicity was analyzed using an Olympus BX51 microscope (Olympus). Images were acquired 
using an Olympus DP72 digital camera (Olympus). 
 
2.9. Statistical analysis 
The data of the in vivo experiments were reported as mean ± SE. AUC analysis was measured 
using the GraphPad Prism v6 software and expressed as relative units. Results were analysed 
using the Student’s t-test, considering statistically significant the observed differences at a 
probability p<0.05. Statistical calculations were performed using SPSS software v21. 
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3. Results and discussion 
Upon systemic injection in mouse models of CXCR4+ human cancers, protein nanoparticles 
formed by T22-GFP-H6 and other derived self-assembling proteins are stable in blood and 
accumulate, intracellularly, in tumoral tissues, with poor or not detectable presence in non-
target tissues [21, 35]. They show a first half-life of around 20 min to biodistribute in the 
blood compartment, followed by a longer elimination phase that yielded a high recirculation 
time of around 1 day [36, 37]. T22-GFP-H6 was used as a scaffold to accommodate the 
fusogenic peptide HA2 [27-29] (in alternative insertion sites) and to test then the 
combination of this membrane-active peptide, that acts in a receptor-independent way, and 
T22, a specific ligand of the tumoral marker CXCR4 [38]. To discriminate between potential 
exclusive or cooperative effects of HA2 and T22, we planned to study the biodistribution of 
T22-HA2-GFP-H6 and T22-GFP-HA2-H6 (Figure 1 A), in a mouse model of CXCR4+ human 
colorectal cancer. Previous to that, we determined that these proteins assembled as stable 
nanoparticles of 30 and 45 nm respectively (Figure 1 B), that while being all fluorescent, 
showed differential emission values (Figure 1 A, bottom). In addition, they were stable in 
serum upon prolonged in vitro incubation (Figure 1 C) and efficiently penetrate cultured 
CXCR4+ HeLa cells, being nicely traceable by their fluorescence (Figure 1 D). However, these 
proteins exhibited differential degrees of CXCR4-dependent cell penetration in cell culture 
(Figure 1 A, [33]), being the highest in the case of T22-GFP-H6 and negligible in the case of 
T22-HA2-GFP-H6. This indicated that HA2 reduced, at least in vitro, the CXCR4-specificity in 
cell penetration regarding the parental T22-GFP-H6. Samples to be administered to animals 
were also fluorescent enough for in vivo tracking (Figure 1 E), with degree of emission in 
agreement with the specific fluorescence of the protein materials (Figure 1 A, bottom). 
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In a next step, we administered intravenously T22-HA2-GFP-H6 and T22-GFP-HA2-H6, and 
the parental T22-GFP-H6 protein acting as control (Figure 1 A), in mice bearing M5 
subcutaneous colorectal cancer (CRC) tumors with high expression of CXCR4 [39]. At 
different times upon single dose injections, T22-GFP-H6 accumulated in subcutaneous 
tumors at levels comparable to those previously described in similar animal models [21]. 
Interestingly, T22-HA2-GFP-H6 nanoparticles rendered a numerically similar result (Figure 2 
A, B).  However, a fast and efficient tumor retention of T22-GFP-HA2-H6 was unexpectedly 
observed, peaking between 2 and 5 h (Figure 2 C), that was necessarily linked to the 
accommodation of the viral HA2 peptide at the particular site between GFP and H6 modules 
(Figure 1 A). None of these proteins were observed at significant levels in non-target organs, 
at exception of some background of T22-GFP-HA2-H6 in the liver (Figure 3 A, B). However, 
the histopathology of liver and kidney in T22-GFP-HA2-H6-treated animals revealed a 
complete absence of lesions, indicative of no side toxicity (Figure 3 C) and supporting the 
biological safety of the protein.  
In cell culture, T22-GFP-HA2-H6 showed a very efficient CXCR4+ cell penetrability, around 
three-fold over the parental T22-GFP-H6 (specially at low protein doses) (Figure 1D, [33]), 
what is in nice agreement with the data obtained in animal models (Figure 2). However, in 
our defined experimental setting up, the fraction of protein that penetrated HeLa cells via 
CXCR4 was reduced from almost 70 % (in the parental T22-GFP-H6), to around 30 % (Figure 1 
C). This fact indicated that the presence of HA2, in this precise insertion site, minimized the 
CXCR4 specificity of the material, probably linked to the receptor-independent fusogenic 
character conferred by the viral segment that enhanced, at the same time and as expected, 
cell penetrability. Therefore, an obvious concern was whether the extraordinary tumor 
targeting manifested by T22-GFP-HA2-H6 was the result of the expected CXCR4 selectivity or 
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it was rather mediated by a combination of the cell-penetrating properties of HA2 and of an 
enhanced permeability and retention (EPR) effect [40, 41].  
To discriminate between these two possibilities, an in vivo competition experiment was 
designed in which the CXCR4 antagonist, AMD3100 [42-47], was used to block tumor 
accumulation of the administered protein materials. As observed (Figure 4 A, B), the 
antagonist dramatically minimized the occurrence of T22-GFP-H6 nanoparticles in tumoral 
tissues, supporting again the role of T22 in active targeting for CXCR4+ cancers. Interestingly, 
AMD3100 equally reduced the tumor accumulation of T22-GFP-HA2-H6 nanoparticles, at 
levels comparable to those determined for T22-GFP-H6 (Figure 4 B). This result confirmed 
that T22 was fully active in T22-GFP-HA2-H6 as a targeting agent, and even a certain 
reduction of specificity could not be completely discarded, the tumor deposition of this 
construct was the result of an active targeting process. AMD3100 did not promote any 
important reduction in the levels of the protein in liver and kidney, supporting the 
background nature of the GFP emission in these non-target organs. The numerical analyses 
of the accumulated materials (area below the curve, Figure 4 C), was fully convincing 
regarding the superiority of T22-GFP-HA2-H6 as a CXCR4-targeted material, that combined 
the cell specificity of T22 and the cell-penetrating abilities empowered by HA2. HA2 activities 
were clearly dependent of the insertion site, as in T22-HA2-GFP-H6, this segment failed to 
enhance the properties of the protein material relevant to its intended roles as drug vehicle. 
Clearly, the accommodation site and molecular environment was relevant to the fusogenic 
properties of the whole construct.  
 
4. Conclusions 
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The combination of a tumor-homing peptide (T22) and a fusogenic peptide (HA2) in modular 
protein nanoparticles dramatically enhances the selective and efficient accumulation of the 
material in target tissues, proving cooperativity (rather than exclusiveness) between 
membrane activity and receptor-based tumor cell targeting. The specific binding to the 
tumoral marker CXCR4 appears to be higher in the animal models compared to the cell 
culture, probably due to the smaller amounts of protein that reach targeted cell per time 
unit. The functional recruitment in self-assembling protein nanoparticles is then seen here as 
a powerful approach to minimize lysosomal degradation of protein materials, a major 
bottleneck in the protein-based intracellular delivery of drugs and other molecules [20] in 
clinical or diagnostic contexts. In particular, the T22-GFP-HA2-H6 protein nano-carrier could 
be used to develop highly potent anticancer therapies, selectively delivered to the cytosol of 
CXCR4+ cancer cells. This can be done by the generation of nanoconjugates that incorporate 
low molecular weight chemotherapeutics, unstable at lysosomal pH values [48], or protein-
only nanoparticles integrating antitumor protein domains [37].  
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Figure 1. Protein materials and their respective properties. A. Schematic representation of 
the polypeptidic building blocks used in the study. Box sizes are only indicative. T22 is a 
CXCR4 specific ligand [38]. L designates the peptidic linker GGSSRSS. HA2 is the fusogenic 
HA2 peptide from the influenza virus hemagglutinin [27-29]. GFP is the enhanced GFP 
version [49]. H6 is a hexahistidine tail. Details of the aa sequences can be found elsewhere 
[33]. A summary of relevant properties of the nanoparticles is found in the table at the 
bottom. The percentage of nanoparticle entrance inhibited by the CXCR4 antagonist 
AMD3100 in cell culture had been previously determined [33]. B. Representative FESEM 
images of the assembled nanoparticles. Bars represent 40 nm. C. Stability of T22-GFP-H6, 
T22-HA2-GFP-H6 and T22-GFP-HA2-H6 in human serum determined by Western blot, upon 
incubation with human serum at 37 ºC (at 0, 2, 5 and 24 h). M indicates the molecular 
markers. D. Isosurface representation of cultured HeLa cells within a 3D volumetric z axes 
stack upon incubation with 0.5 µM protein nanoparticles for 24 h. The cell membrane was 
labelled with CellMask (rendering a red signal), the nuclear DNA was labelled with Hoeschst 
33342 (rendering a blue signal) and protein nanoparticles are seen in green because of their 
intrinsic fluorescence. Bars indicate 5 μm. E. Fluorescence of the materials just before in vivo 
i.v. administration.   
  






Figure 2. Tumor biodistribution of nanoparticles in a mouse model of human colorectal 
cancer highly expressing CXCR4. A. Representative ex vivo images of GFP-emitted 
fluorescence by the tumor at 2 h, 5 h and 24 h after the i.v. administration of 200 μg dose of 
each protein nanoparticle in the patient-derived M5 subcutaneous colorectal cancer model. 
B. Quantitative analysis of tumor emitted fluorescence by each nanoparticle at the studied 
time points. Data were corrected by specific fluorescence of each protein, so they are 
indicative of protein amounts. *, p<0.05. 
 





Figure 3. Biodistribution and lack of toxicity of the nanoparticles in non-target organs. A. 
Representative ex vivo images of GFP-emitted fluorescence in the main non-tumor organs at 
2 h, 5 h and 24 h after the i.v. injection of 200 μg dose of each protein nanoparticle in the SC 
M5 colorectal cancer model B. Quantitative analysis of liver- and kidney- emitted 
fluorescence by each nanoparticle at the studied time points.. *, p<0.05; **, p<0.01. C. 
Absence of histopathological alterations in liver or kidney in H&E stained tissue sections, at 
the studied time points after the administration of the T22-GFP-HA2-H6 nanoparticle. Bars 
indicate 250 μm. 
  






Figure 4. CXCR4-dependent biodistribution of nanoparticles and exposure in tumor and 
non-tumor organs. A. Inhibition of T22-GFP-H6 or T22-GFP-HA2-H6 nanoparticle 
accumulation in tumor tissue 5 h after their i.v. injection (200 μg dose) by the administration 
of the CXCR4 antagonist AMD3100 (10 mg/kg dose, 1 h before, 1 h after and 2 h after 
nanoparticle injection). B. Quantitation of the fluorescence-emitted in tumor (images in 
panel A), liver and kidney. Notice CXCR4-dependence for tumor accumulation for both 
nanoparticles and their lack of receptor-dependence and low level of accumulation in liver 
and kidney.  C. Graphic representation of total nanoparticle exposure (Area under the curve: 
AUC = FLI emission x time (h)) registered in tumor and non-tumor organs along the studied 
period (2-24 h) for all three tested nanoparticles (200 μg dose) using the SC M5 colorectal 
cancer model, and its quantitation. Fluorescence emission intensity (FLI) signal from 
experimental mice was calculated subtracting the FLI auto-fluorescence of control buffer-
treated mice. FLI, fluorescent intensity (expressed as average radiant efficiency). 
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